+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

AIDS-defining illnesses: a comparison between before and after commencement of highly active antiretroviral therapy (HAART)



AIDS-defining illnesses: a comparison between before and after commencement of highly active antiretroviral therapy (HAART)



Current HIV Research 5(5): 484-489



Attempts to address the significant impact of HAART on medical variables on the Malaysian HIV/AIDS population have yet to be evaluated. This study aims to analyze the proportions of AIDS-defining illnesses (ADIs) before and after HAART. A retrospective study was carried out on 128 new cases of HIV infected patients who first commenced HAART in 2004 at the national HIV reference center. Before commencement of HAART, 76 clinical episodes of ADIs were recorded in 52 patients. Most common being pulmonary Mycobacterium tuberculosis (28.9%), PCP (27.6%) and disseminated and extrapulmonary Mycobacterium tuberculosis (11.8%). During HAART, 8 clinical episodes of ADIs were documented in 7 patients with a median time of onset of 10 weeks after initiation of HAART (range, 4-36 weeks). The median CD4 count at the time of the commencement of HAART for these patients was 11 cells/mm(3). ADIs reported include PCP (2 episodes), disseminated and extrapulmonary Mycobacterium tuberculosis (2 episodes), extrapulmonary cryptococcosis (1 episode), esophageal candidiasis (1 episode), recurrent pneumonia (1 episode) and disseminated or extrapulmonary histoplasmosis (1 episode). Three (37.5%) of these occurred despite a reduction of viral load by at least 2 log(10) and an increased in the CD4 cell count. In conclusion, ADIs can still present after the initiation of successful HAART especially in those with CD4 counts below 100 cells/mm(3). In Malaysia, ADIs are the major causes of HIV/AIDS associated morbidity and mortality, thus increased awareness on the management of these illnesses is warranted especially in the months following HAART.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 051294436

Download citation: RISBibTeXText

PMID: 17896968


Related references

Aids-Defining Illnesses: A Comparison Between Before and After Commencement of Highly Active Antiretroviral Therapy (Haart). Current Hiv Research 5(5): 484-489, 2007

The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic. Journal of Infection 42(2): 134-139, 2001

Features of AIDS and AIDS defining diseases during the highly active antiretroviral therapy (HAART) era, compared with the pre-HAART period: a case-control study. Sexually Transmitted Infections 76(2): 145-B-146, 2000

Effects of the introduction of highly active antiretroviral therapy (HAART) on the temporal trend of diagnosis of AIDS and AIDS-defining disorders. Le Infezioni in Medicina 8(3): 134-138, 2000

AIDS defining lymphomas in the era of highly active antiretroviral therapy (HAART): an African perspective. Transfusion and Apheresis Science 37(1): 63-70, 2007

Effect of highly active antiretroviral therapy on multiple AIDS-defining illnesses among male HIV seroconverters. American Journal of Epidemiology 163(4): 310-315, 2005

Anterior segment involvement in HIV-related eye disease after the commencement of highly active antiretroviral therapy (HAART). Klinische Monatsblatter für Augenheilkunde 216(2): 61-67, 2000

Posterior segment involvement in HIV-related eye disease after commencement of highly-active antiretroviral therapy (HAART). Klinische Monatsblatter für Augenheilkunde 216(2): 68-74, 2000

A Comparison of the Diabetes Risk Score in HIV/AIDS Patients on Highly Active Antiretroviral Therapy (HAART) and HAART-Naïve Patients at the Limbe Regional Hospital, Cameroon. Plos one 11(5): E0155560, 2016

Relationship of chronic hepatitis C infection to rates of AIDS-defining illnesses in a Canadian cohort of HIV seropositive individuals receiving highly active antiretroviral therapy. HIV Clinical Trials 13(2): 90-102, 2012

AIDS and cancer in the era of highly active antiretroviral therapy (HAART). European Journal of Cancer 37(10): 1316-1319, 2001

AIDS associated cancers in the era of highly active antiretroviral therapy (HAART). Przeglad Epidemiologiczny 61(3): 529-534, 2007

A comparison of exposure groups in the EuroSIDA study: Starting highly active antiretroviral therapy (HAART), response to HAART, and survival. JAIDS Journal of Acquired Immune Deficiency Syndromes 22(4): 369-378, 1999

A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. Journal of Acquired Immune Deficiency Syndromes 22(4): 369-378, 1999

Role of Mycobacterium xenopi disease in patients with HIV infection at the time of highly active antiretroviral therapy (HAART). Comparison with the pre-Haart period. Tuberculosis 83(5): 319-328, 2003